Abstract
Oral delivery of peptide, protein and vaccine biotechnology products remains the major challenge in drug delivery technology. In the main, these agents are administered to patients by injection, infusion or by subcutaneous implants. Oral delivery of intact peptide-based products is attractive because it offers improved convenience and patient compliance, and this will result in reduced overall healthcare costs. Taking into account the intestinal site of absorption and the physico-chemical properties of the agent, these labile compounds can be successfully formulated for oral delivery using intestinal-protective-, targeting- and epithelial-permeating approaches. Some of the more innovative current technologies are reviewed for these classes of biotech products.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
